

Claims

1. A salt of Formula III:




Formula III

said salt being a combination of a compound of Formula I and an acid of Formula II:



Formula I



Formula II


in a ratio of 1:n,

wherein

X is OH or H; and

n is 0.5 or 1.

2. The salt of Formula III according to claim 1, wherein X is OH thereby providing a salt of Formula IIIa being a combination of the compound of Formula I and tartaric acid:



Formula IIIa .

3. The salt of Formula IIIa according to claim 2, wherein the tartaric acid is L-(+)-tartaric acid.

4. The salt of Formula IIIa according to claim 2, wherein the tartaric acid is D-(-)-tartaric acid.

5. The salt of Formula III according to any one of the preceding claims, wherein n is 0.5.

6. The salt according to any one of the preceding claims, characterised by being crystalline.

7. The salt of Formula III according to any one of claims 1-6, characterized by an XRP diffractogram comprising a peak at 27.4 degrees 2θ and one or more peaks selected from the following: 17.8, 19.5, 19.9, 21.6 degrees 2θ, and/or by an XRP diffractogram as shown in Figure 1.

8. The salt of Formula III according to any one of the preceding claims, wherein one or more of the hydrogen atoms of the compound of Formula I is/are replaced with deuterium.

9. The salt of Formula III according to any one of the preceding claims, wherein said salt changes its weight by about ± 0.2% by weight or less at any humidity, such as any relative humidity such as a relative humidity of 80% measured at a temperature from 20 °C to 25 °C.

10. The salt of Formula III according to any one of claims 1-7, which has a water solubility from 53 mg/mL to 106 mg/mL and/ or a melting point of 181.5 °C, and/or wherein said salt is chemically stable in methanol solution at room temperature, at a temperature of 37 °C and/or at a temperature of 50 °C for 48 hours or more such as for 168 hours or more.

11. A pharmaceutical composition comprising the salt of Formula III according to any one of the preceding claims in admixture with a pharmaceutically acceptable excipient, carrier and/or diluent.

12. The salt of Formula III as defined in any one of claims 1-10, or the pharmaceutical composition according to claim 11 for use as a medicament.

13. Use of a salt of Formula III as defined in any one of claims 1-10 or a pharmaceutical composition according to claim 11 for the manufacture of a medicament for the treatment and/or prevention of a disease, disorder and/or condition selected from the group consisting of dementia, cognitive impairment, autism spectrum disorder, affective disorder, schizophrenia, anxiety disorder, attention deficit hyperactivity disorder (ADHD), movement disorder, postural instability and pathological apathy.

14. The use according to claim 13, wherein the disease, disorder and/or condition is pathological apathy.

15. The use according to any one of claims 13 or 14, wherein the pathological apathy is associated with a neurodegenerative disease such as dementia, Alzheimer´s disease or Parkinson´s disease.